Breast Cancer
Breast CANCER
Her2
HER2 is a growth-promoting protein on the outside of all breast cells. Breast cancer cells with higher than normal levels of HER2 are called HER2-positive. These cancers tend to grow and spread faster than other breast cancers but are much more likely to respond to treatment with drugs that target the HER2 protein.
BRCA
We offer testing of both germline and somatic mutations to guide treatment pathways and give genetic information to families with a history of breast cancer
PD-L1
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Recent discoveries in TNBC have shown that the higher the expression of the surface molecule PD-L1 in the cancer cells, the better the response of patients to immunotherapy. Testing is available to clinicians in order to guide treatment options in immunotherapy.
Pik3CA cf & Pik3CA Tissue
PIk3CA is a common genetic mutation in breast cancer patients and the gene has been associated with tumour growth, therapy resistance and poor prognosis. Patients who are HR+/HER2- may be able to take new targeted kinase inhibitors if they are one of the ~40% of patients with an activating PIK3CA mutation. CCL offers PIK3CA mutation analysis from tumour samples and liquid biopsies covering the Mutation hotspots in Exon 7, 9 and 20.
Further information
For more detail on screening and early cancer detection, please visit our Cancer Testing page.
For more detail on tests to investigate cancer aggressiveness or to guide treatment, please visit the Companion Diagnostics page.
USEFUL DOWNLOADS
ACCESS
If you are a healthcare professional, please contact us. If you are a patient, please refer your healthcare professional to our website and ask them to get in touch. Please note that Cambridge Clinical Laboratories HCP services are only available through a professional healthcare provider.
If you would like to use one of these services, please contact us.